BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.